PAMIDRONATE DISODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pamidronate disodium and what is the scope of freedom to operate?
Pamidronate disodium
is the generic ingredient in two branded drugs marketed by Novartis, Aesgen, Am Regent, Areva Pharms, Dr Reddys, Fresenius Kabi Usa, Hikma, Hospira, Mn Pharms, Mylan Labs Ltd, Sagent Pharms Inc, Sun Pharma Global, and Teva Pharms Usa, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.Two suppliers are listed for this compound.
Summary for PAMIDRONATE DISODIUM
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 13 |
| NDAs: | 15 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 159 |
| Clinical Trials: | 8 |
| Patent Applications: | 7,012 |
| What excipients (inactive ingredients) are in PAMIDRONATE DISODIUM? | PAMIDRONATE DISODIUM excipients list |
| DailyMed Link: | PAMIDRONATE DISODIUM at DailyMed |
Recent Clinical Trials for PAMIDRONATE DISODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Peking Union Medical College Hospital | Phase 1 |
| The Hospital for Sick Children | N/A |
| National Cancer Institute (NCI) | Phase 1 |
Pharmacology for PAMIDRONATE DISODIUM
| Drug Class | Bisphosphonate |
US Patents and Regulatory Information for PAMIDRONATE DISODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 078156-001 | Aug 19, 2008 | AP2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sagent Pharms Inc | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 078373-001 | Dec 23, 2008 | AP1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan Labs Ltd | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 078520-002 | Oct 31, 2008 | AP2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan Labs Ltd | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 078520-001 | Oct 31, 2008 | AP2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fresenius Kabi Usa | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 076207-002 | May 17, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PAMIDRONATE DISODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-001 | Oct 31, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-003 | May 6, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-004 | May 6, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-004 | May 6, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-003 | May 6, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
